BPC-157 TB-500 FAQ

Definitions

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 ^[1][7]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack.

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere ^[11].

What is the BPC-157 and TB-500 blend used for in research?

Preclinical, mostly rodent, research on the two constituents covers tendon, ligament, muscle and bone repair, wound and soft-tissue healing, and angiogenesis ^[5][6]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study ^[11].

What is the difference between BPC-157 and TB-500?

They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/nitric-oxide and growth-hormone-receptor pathways; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin ^[2][3]. Different sequences, sizes and mechanisms.

Mechanism and Combination

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

In preclinical models, yes — by separate routes. BPC-157 up-regulates VEGFR2 and promotes VEGFR2 internalization with downstream Akt-eNOS signaling (increased vessel density and faster blood-flow recovery in ischemic rat muscle), and Thymosin Beta-4 promotes angiogenesis, wound healing and hair-follicle development by increasing endothelial migration ^[2][6]. No controlled combination study has measured the combined effect ^[11].

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair ^[2][3]. No head-to-head or combination study has defined a synergistic dose, ratio or endpoint.

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. Crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization ^[3].

How does BPC-157 work compared to TB-500?

BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS up-regulation and Src-Caveolin-1-eNOS vasomotor modulation), while TB-500 supplies an intracellular actin-sequestration signal (1:1 G-actin binding via the LKKTETQ motif) ^[2][3][8]. They act through complementary but largely non-overlapping pathways — the basis of the unproven synergy claim.

Evidence and Efficacy

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human, "no clinical safety data") makes no mention of TB-500 or combination use ^[11]. "Synergy" is an extrapolation from each peptide's separate, largely non-overlapping mechanism.

Are there human clinical trials on the BPC-157 + TB-500 combination?

None. There are no controlled clinical trials of the combination for any indication ^[13]. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide ^[4].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures and enhanced tendocyte outgrowth ^[5]. These are preclinical, single-compound results, not human or combination evidence.

Does BPC-157 and TB-500 help muscle tears and recovery?

Preclinical studies report BPC-157 aiding tissue repair via cytoprotective and angiogenic signaling, and Thymosin Beta-4 promoting cell migration; however, a 6-month Thymosin Beta-4 mdx-mouse study increased regenerating fibers but produced no gain in strength ^[4][2]. Findings are animal-model and single-compound.

Does the BPC-157 TB-500 blend help wound healing?

In animal models, Thymosin Beta-4 promoted angiogenesis and wound healing — including restored angiogenesis in aged animals with otherwise poor healing — and BPC-157 shows multi-tissue cytoprotection ^[6][2]. These are preclinical, single-compound results; the blend itself has no controlled wound-healing trial ^[11].

Side Effects and Safety Signals in Research

What are the side effects of BPC-157 and TB-500?

Long-term human safety is unknown for both constituents and the blend. The principal documented concern is a tumor signal: Thymosin Beta-4 is implicated in metastasis and tumor angiogenesis, so the same pro-angiogenic, pro-migratory properties that aid repair could theoretically support tumor progression ^[4]. Combining two unapproved peptides doubles the uncertainty. These are the side effects and safety signals on record.

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis in tumor models; this is a theoretical safety consideration, not a demonstrated cancer-causing effect of TB-500 in humans ^[4]. No human data establish either safety or harm for the TB-500 fragment in this respect.

Is TB-500 bad for your heart?

Human intravenous full-length Thymosin Beta-4 has been well tolerated in Phase 1 dosing (up to 1260 mg, and microgram-per-kilogram regimens), but those data are for the full-length protein, not the heptapeptide ^[14]. A 6-month mdx-mouse study of chronic Thymosin Beta-4 showed no improvement in cardiac function, and no controlled cardiac-safety data exist for the TB-500 fragment or the blend ^[4].

Pharmacokinetics, Handling, and Timeline

What is the half-life of BPC-157 and TB-500?

No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[1][14].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity and the actual ratio in unregulated material are not guaranteed. This is research-handling context, not a human-use instruction.

How often should you inject BPC-157 and TB-500?

There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing (for example TB-500 / Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for 6 months in one model); community "loading then maintenance" protocols have no controlled-trial basis ^[4][11].

How do you cycle BPC-157 and TB-500?

No validated cycle exists. Community "loading then maintenance" protocols and fixed-ratio vials (for example 10 mg plus 10 mg) have no basis in controlled human trials and should not be presented as validated dosing ^[11].

How long does it take BPC-157 and TB-500 to work for an injury?

There is no validated human timeline. The underlying evidence is preclinical and single-compound, with study durations ranging from acute injury models to a 6-month Thymosin Beta-4 mdx-mouse study; no controlled trial of the combination has measured an onset in humans ^[4][11]. Any specific "weeks to heal" claim outruns the published data.

Legal and Regulatory

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither constituent is FDA-approved and the blend has no approved indication. The FDA placed BPC-157 in Category 2 of bulk drug substances for 503A compounding — identified as raising significant safety risks — effective with the September 29, 2023 update, and the same update placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2 ^[15][16]. Both are also WADA-prohibited.

Can you get BPC-157 from a compounding pharmacy?

BPC-157 is in FDA 503A Category 2 — identified as raising significant safety risks and not within the FDA's enforcement-discretion policy for 503A compounding — effective with the September 29, 2023 update ^[15]. A compounder may use a bulk substance only if it has a USP/NF monograph, is a component of an approved drug, or is on the FDA's 503A bulks list; a substance flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17].

Is Wolverine legal?

There is no approved "Wolverine" product, and neither constituent is an FDA-approved drug. Both BPC-157 and the TB-500 fragment sit in FDA 503A Category 2 — not within the agency's enforcement-discretion policy for compounding — as of the September 29, 2023 list update ^[15][16]. The full picture is on the Wolverine legal status and FDA 503A category page.

What is the FDA 503A status of Wolverine?

Both constituents are FDA 503A Category 2 bulk drug substances — identified as presenting significant safety risks and not covered by FDA's enforcement-discretion policy for 503A compounding — effective with the September 29, 2023 update ^[15][16]. The blend as such has no separate FDA classification; it inherits the Category 2 status of its two constituents.